Vikram Purohit Analyst PerformanceExecutive Director, Equity Analyst at Morgan StanleyVikram Purohit is a stock analyst at Morgan Stanley in the medical sector, covering 10 publicly traded companies. Over the past year, Vikram Purohit has issued 17 stock ratings, including buy and hold recommendations. While full access to Vikram Purohit's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Vikram Purohit's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings27 Last 5 YearsBuy Recommendations50.00% 13 Buy RatingsCompanies Covered10 Unique Companies Ratings Distribution26RatingsDistribution of strong buy, buy, hold, and sell ratings by Vikram Purohit.RatingPercentageCount Strong Buy0.0%0 ratings Buy50.0%13 ratings Hold50.0%13 ratings Sell0.0%0 ratingsOut of 26 total stock ratings issued by Vikram Purohit at Morgan Stanley, the majority (50.0%) have been Buy recommendations, followed by 50.0% Hold.Best & Worst CallsBest Call000.0%ASNDMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%TBPHOct 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ10 companiesVikram Purohit, an analyst at Morgan Stanley, currently covers 10 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical10 companies100.0%Vikram Purohit of Morgan Stanley specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE6 companies60.0%MED - DRUGS2 companies20.0%MEDICAL SERVICES1 company10.0%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC1 company10.0% Vikram Purohit's Ratings History at Morgan Stanley Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsRXRXRecursion Pharmaceuticals5/14/2026Boost Price Target$3.14$5.50Equal Weight$0.0000.00% ROICMPSCompass Pathways5/14/2026Boost Price Target$10.72$17.00Overweight$0.0000.00% ROIHALOHalozyme Therapeutics5/12/2026Lower Price Target$72.82$93.00Overweight$0.0000.00% ROICMPSCompass Pathways3/25/2026Lower Price Target$5.68$16.00Overweight$0.0000.00% ROICMPSCompass Pathways2/18/2026Boost Price Target$7.63$18.00Overweight$0.0000.00% ROIINCYIncyte2/11/2026Set Price Target$98.63$102.00$0.0000.00% ROIABSIAbsci1/8/2026Downgrade$4.02$4.32Equal Weight$0.0000.00% ROIINCYIncyte1/6/2026Boost Price Target$104.53$94.00Equal Weight$0.0000.00% ROIINCYIncyte12/8/2025Boost Price Target$95.73$92.00Equal Weight$0.0000.00% ROICMPSCompass Pathways11/5/2025Boost Price Target$5.84$11.00Overweight$0.0000.00% ROIHALOHalozyme Therapeutics10/20/2025Lower Price Target$66.87$79.00Overweight$0.0000.00% ROIABSIAbsci8/18/2025Lower Price Target$2.93$5.89Overweight$0.0000.00% ROIHALOHalozyme Therapeutics8/18/2025Boost Price Target$67.27$80.00Overweight$0.0000.00% ROIHALOHalozyme Therapeutics8/6/2025Upgrade$60.81$75.00Overweight$0.0000.00% ROIABSIAbsci7/28/2025Lower Price Target$2.89$6.40Overweight$0.0000.00% ROIRXRXRecursion Pharmaceuticals7/3/2025Initiated Coverage$5.21$5.00Equal Weight$0.0000.00% ROIRXRXRecursion Pharmaceuticals6/16/2025Lower Price Target$5.00$5.00Equal Weight$0.0000.00% ROIHALOHalozyme Therapeutics5/14/2025Downgrade$49.84$62.00Equal Weight$00.0000.00% ROIASNDAscendis Pharma A/S5/5/2025Upgrade$172.06$250.00Overweight$000.0000.00% ROIRXRXRecursion Pharmaceuticals4/10/2025Lower Price Target$4.16$8.00Equal Weight$0.0000.00% ROIINCYIncyte3/24/2025Lower Price Target$61.92$65.00Equal Weight$00.0000.00% ROIAXSMAxsome Therapeutics2/27/2025Boost Price Target$128.33$190.00Overweight$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel NicolausRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
